Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound hypoglycemic preparation containing liraglutide and preparation method thereof

A technology of liraglutide and compound prescription is applied in the field of compound hypoglycemic preparations containing liraglutide and its preparation, which can solve the problems of passivation of target organs, single component, and reduced curative effect, so as to promote regeneration and change thirst. The effect of liking drink and restoring secretion function

Inactive Publication Date: 2017-01-11
卢连伟
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the ingredients of the drugs used to treat diabetes on the market are single, the effect is only on a certain link of lowering blood sugar. Long-term use will cause the target organ to be inactivated, which will lead to the phenomenon that the curative effect will decrease after a period of time.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: A compound hypoglycemic preparation containing liraglutide, including the following components by weight: 9 parts of liraglutide, 28 parts of yellow ginseng polysaccharide, 22 parts of tetrandrine, 16 parts of saccharin 12 parts of spirulina polysaccharide, 8 parts of mixed kinase, 7 parts of potassium magnesium aspartate, 5 parts of fenofibrate, 3 parts of calcium dobesilate, 1 part of vascular endothelial growth factor, 0.8 part of duloxetine , 0.2 part of monosialotetrahexosyl ganglioside, 0.1 part of tripterygium glycoside, 0.09 part of pentoxifylline, 0.05 part of edaravone, 5 parts of propylene glycol, 1 part of sodium p-aminobenzoate, propyl gallate 0.01 part.

[0018] Wherein, the component of the mixed kinase is a mixture prepared from hexokinase, phosphofructokinase-1, and pyruvate kinase in a mass ratio of 4:2:1; the mixed kinase mainly promotes the oxidative absorption of sugar.

[0019] Wherein, the preparation method of the spirulina polysaccha...

Embodiment 2

[0028]Example 2: A compound hypoglycemic preparation containing liraglutide, including the following components by weight components: 13 parts of liraglutide, 34.5 parts of yellow ginseng polysaccharide, 29.5 parts of tetrandrine, 19.5 parts of saccharin 13.5 parts of spirulina polysaccharide, 9.5 parts of mixed kinase, 8 parts of potassium magnesium aspartate, 7 parts of fenofibrate, 4 parts of calcium dobesilate, 2.5 parts of vascular endothelial growth factor, and 1 part of duloxetine , 0.3 parts of monosialotetrahexosyl ganglioside, 0.3 parts of tripterygium glycosides, 0.105 parts of pentoxifylline, 0.065 parts of edaravone, 8.5 parts of propylene glycol, 1.5 parts of sodium p-aminobenzoate, propyl gallate 0.025 parts.

[0029] Wherein, the component of the mixed kinase is a mixture prepared from hexokinase, phosphofructokinase-1, and pyruvate kinase in a mass ratio of 4:2:1; the mixed kinase mainly promotes the oxidative absorption of sugar.

[0030] Wherein, the prepar...

Embodiment 3

[0039] Example 3: A compound hypoglycemic preparation containing liraglutide, including the following components by weight components: 17 parts of liraglutide, 41 parts of yellow ginseng polysaccharide, 37 parts of tetrandrine, 23 parts of saccharin 15 parts of spirulina polysaccharide, 11 parts of mixed kinase, 9 parts of potassium magnesium aspartate, 9 parts of fenofibrate, 5 parts of calcium dobesilate, 4 parts of vascular endothelial growth factor, 1.2 parts of duloxetine , 0.4 parts of monosialotetrahexosyl ganglioside, 0.5 parts of tripterygium glycosides, 0.12 parts of pentoxifylline, 0.08 parts of edaravone, 12 parts of propylene glycol, 2 parts of sodium p-aminobenzoate, propyl gallate 0.04 parts.

[0040] Wherein, the component of the mixed kinase is a mixture prepared from hexokinase, phosphofructokinase-1, and pyruvate kinase in a mass ratio of 4:2:1; the mixed kinase mainly promotes the oxidative absorption of sugar.

[0041] Wherein, the preparation method of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound hypoglycemic preparation containing liraglutide and a preparation method thereof. The compound hypoglycemic preparation comprises the following components: liraglutide, Sphallerocarpus Racills polysaccharides, tetrandrine, saccharicterpenin, Spriulina polysacchrides, mixed kinases, potassium magnesium aspartate, fenofibrate, calcium dobesilate, vascular endothelial growth factor, duloxetine, monosialoteterahexosyl ganglioside, tripterygium glycosides, pentoxifylline, and edaravone. The compound hypoglycemic preparation of the invention has a hypoglycemic effect by rectifying metabolic disorder, restoring renal metabolic function, restoring insulin secretion function, promoting regeneration of islet cells, and repairing damaged islet cells; and can resorb and utilize the blood excessive sugar while restoring renal metabolic function. The compound hypoglycemic preparation of the invention is used for eliminating diabetes and the diabetic complications of eyes, kidneys, heart, nerves and limbs, and has the characteristics of distinct therapeutic effect and stable low side effects.

Description

technical field [0001] The invention relates to the technical field of diabetes medication, in particular to a compound hypoglycemic preparation containing liraglutide and a preparation method thereof. Background technique [0002] Diabetes mellitus is a common endocrine and metabolic disease with a genetic tendency. Its pathophysiological changes are relatively insufficient insulin secretion, which causes metabolic disorders such as sugar, fat, and protein. Symptoms of thirst, which in turn lead to diabetes complications. And diabetic complication is a kind of common chronic complication, and ill consequence is quite serious, foot disease (foot gangrene, amputation), nephropathy (renal failure, uremia), eye disease (blurred, blindness), encephalopathy ( Cerebrovascular disease), heart disease, skin diseases, sexually transmitted diseases, etc. are the most common complications of diabetes, and are the main factors leading to the death of diabetic patients. Therefore, diab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/45A61P3/10A61K38/26A61K38/18A61K36/37A61K31/715A61K31/7032A61K31/522A61K31/4748A61K31/4152A61K31/381A61K31/216A61K31/198A61K31/185
Inventor 卢连伟
Owner 卢连伟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com